New combo therapy targets hard-to-treat solid tumors
Disease control
Not yet recruiting
This study tests a new drug, JCXH-211, injected directly into tumors along with an anti-PD-1 antibody given through an IV. It is for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and tolerable …
Phase: PHASE1, PHASE2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC